Lasa Supergenerics LimitedQ1 FY27 Results & Financial Update
Lasa Supergenerics Limited: Q1 FY27 standalone results and company financials – revenue ₹1.23 Cr, PAT ₹-3.58 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Lasa Supergenerics price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Lasa Supergenerics Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Lasa Supergenerics reported a net loss of INR 3.58 crore for the quarter ended June 30, 2026, alongside revenue from operations of INR 1.23 crore, reflecting the continued paralysis of its core manufacturing footprint.
Manufacturing activity at the Lote Parshuram mother unit has remained completely halted following a major fire incident that occurred on May 18, 2025, which destroyed key inventories, property, plant, and equipment.
Because all downstream units relied on intermediate output from the halted mother unit, secondary operations have also stayed suspended, leaving the company without meaningful commercial production.
Management noted that it is actively exploring alternative arrangements such as contract manufacturing agreements or leasing out facilities, subject to required regulatory approvals.
The financial statements continue to reflect fixed operational overheads, including depreciation of INR 1.57 crore and finance costs of INR 0.14 crore, contributing to the persistent negative profitability.
Profit after tax was ₹-3.58 Cr for the reported quarter. EPS was ₹-0.71 for the reported quarter.
01 · Business model
What does Lasa Supergenerics do?
Lasa Supergenerics Limited operates in the active pharmaceutical ingredients (API) segment, specialising in veterinary and human pharmaceutical products.
The company's core manufacturing operations have historically been anchored at its mother unit situated at Plot No. C-4 in the Lote Parshuram Industrial Area, Ratnagiri, Maharashtra.
Other owned and leased manufacturing facilities of the company depended on intermediate outputs from this primary unit for further processing and production.
02 · Historical context
What shaped the business before this quarter
On May 18, 2025, a severe fire broke out at the company's mother unit (Plot No. C-4) at Lote Parshuram Industrial Area, Ratnagiri, destroying inventories, plant and machinery, and office areas, which halted all production.
As the affected assets were not covered by insurance, an uninsured loss amounting to Rs. 2,057.47 lakhs was recognized as exceptional items in earlier periods.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹1.23 Cr |
| Total income | ₹1.33 Cr |
| Profit before tax | ₹-3.47 Cr |
| Profit after tax | ₹-3.58 Cr |
| EPS | ₹-0.71 |
Financial interpretation
What the reported numbers mean
Profit after tax represented -291.7% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to -283.1% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹0.10 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Revenue from operations for Q1 FY27 stood at INR 1.23 crore, reflecting negligible commercial billing due to the total suspension of manufacturing activities.
An invoice for destroyed goods prior to transfer of risk or ownership is governed by Section 56 of the Indian Contract Act, with revenue recognition suspended and customer advances held under 'Force Majeure Suspense'.
What drove margins
Despite zero meaningful production, the company incurred ongoing fixed overheads including depreciation of INR 1.57 crore and employee benefits expense of INR 0.19 crore, driving negative margins.
Total income reached INR 1.33 crore, supported by INR 0.10 crore in other income, which cushioned the net loss before tax of INR 3.47 crore.
05 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
The company operates in a single business segment, namely Active Pharmaceutical Ingredients (API), making segment reporting under Ind AS 108 inapplicable.
06 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
All manufacturing operations at the C-4 mother unit and dependent downstream units remain completely suspended, with plant utilisation at zero.
Projects, capex and execution
Management is evaluating a recovery and rebuilding strategy, including potential funding arrangements, though physical inspection has been constrained.
07 · Pressure points & risks
What is not going smoothly
An unrecognized labour union initiated a strike outside the factory following non-payment of wages due to financial constraints, obstructing access and preventing professional valuers from conducting technical assessments.
The company faces pending GST demand notices aggregating to Rs. 3,810.93 lakhs for various assessment periods, which are currently being contested.
Due to the suspension of production operations, management has discontinued recognizing Government Grant income on an accrual basis.
08 · Items worth noticing
The line items that can distort a quick read
Customer advances related to destroyed goods prior to transfer of risk have been retained under 'Force Majeure Suspense' as a continuing liability pending legal settlement.
09 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Bank account balances of INR 5.71 lakhs and fixed deposits of INR 26.42 lakhs as of June 30, 2026, could not be confirmed as these accounts are in dormant status.
10 · Beyond the numbers
What changed beyond the numbers
Reported update
Statutory Auditor Review Modification
The statutory auditors issued a modified review report highlighting multiple uncertainties, including asset impairment valuation constraints, going-concern doubts, dormant bank accounts, and unresolved GST demands.
11 · Previous-quarter changes
What changed since the previous quarter
The company posted a net loss of INR 3.58 crore in Q1 FY27 compared to a net loss of INR 4.16 crore in Q4 FY26, as fixed overheads continued in the absence of manufacturing.
12 · Key Q&A
The quarter, answered directly
What does Lasa Supergenerics do?
Lasa Supergenerics Limited operates in the active pharmaceutical ingredients (API) segment, specialising in veterinary and human pharmaceutical products.
What is the clearest takeaway from Q1 FY27?
Lasa Supergenerics reported a net loss of INR 3.58 crore for the quarter ended June 30, 2026, alongside revenue from operations of INR 1.23 crore, reflecting the continued paralysis of its core manufacturing footprint.
What drove revenue or demand?
Revenue from operations for Q1 FY27 stood at INR 1.23 crore, reflecting negligible commercial billing due to the total suspension of manufacturing activities.
What mattered most for margins or profitability?
Despite zero meaningful production, the company incurred ongoing fixed overheads including depreciation of INR 1.57 crore and employee benefits expense of INR 0.19 crore, driving negative margins.
What changed operationally beyond the headline numbers?
All manufacturing operations at the C-4 mother unit and dependent downstream units remain completely suspended, with plant utilisation at zero.
What are the main pressure points disclosed for the quarter?
An unrecognized labour union initiated a strike outside the factory following non-payment of wages due to financial constraints, obstructing access and preventing professional valuers from conducting technical assessments.
13 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
14 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Statutory Clearances and Alternative Arrangements: Monitor progress on securing regulatory clearances, finalising contract manufacturing or leasing arrangements, and resolving factory access and labour disputes.
- 02
Physical Inspection and Insurance/Damage Quantification: Track whether the company succeeds in conducting detailed physical inspections and technical evaluations of plant and machinery damage.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.